As a physician scientist, I lead an active translational and clinical research program in T-cell lymphomas centered around understanding biology in the laboratory, eradiation of molecular disease, dissecting mechanisms of resistance to therapeutics and development of preclinical models to accelerate transition of innovative treatments to clinic. I provide care to patients with PTCL and CTCL at MGH and I am the DF/HCC PI for multiple clinical trials for this population. I am the founder of the PETAL (PEripheral T-cell Lymphoma) consortium, a comprehensive international collaboration of clinical and scientific investigators across 19 sites in 10 countries with expertise in T-cell lymphomas. We at PETAL are committed to accelerating breakthroughs to advance scientific understanding and effective patient care. This is a first of its kind multi-national initiative that will use patient data driven models and leverage artificial intelligence to enable precision medicine and improve global outcomes for patients with T-cell lymphomas. In summary, I am deeply committed to research-infused exceptional patient care, training of next generation investigators and addressing global cancer disparities.

Interest: Molecular characterization and novel immunotherapeutic approaches for T-cell lymphomas

I am a co-investigator in the Jain Lab and a member of PETAL Consortium. I earned my MD from Baylor College of Medicine and am currently an internal medicine resident at Massachusetts General Hospital, planning to pursue a fellowship in hematology-oncology. I aim to contribute to research that advances the care of patients with relapsed and refractory T-cell lymphoma through improved prognostic models and more effective treatment strategies. As part of the Jain Lab, we place an emphasis on research that reflects diverse patient populations and can hopefully translate into practice for oncology providers worldwide. Most recently, my work has centered on LILY-seq, a lineage-informed approach to minimal residual disease, and its utility as a predictor of relapse after autologous stem cell transplantation in peripheral T-cell lymphoma. Outside of the hospital, I enjoy reading, cooking Albanian dishes, and photographing nature.

My name is Kusha Chopra, and I work as a Research Technologist in the Jain Lab. In this cutting-edge translational research lab, I engage in a dynamic range of projects incorporating in-vitro, in-vivo, and clinical skills. My primary project focuses on defining pathways that confer resistance to the CD47-SIRPa myeloid checkpoint. After generating tumors that are resistant to CD47 blocking antibody in ITK-SYK transgenic mouse model of peripheral T-cell lymphoma (TCL), we are now using bulk RNA-sequencing, whole exome sequencing and ATAC-sequencing to elucidate a mechanisms of resistance to this axis. Alongside my talented colleague, Josie, I also work on the multi-center and collaborative MRD project that investigates biomarkers for patients with angioimmunoblastic TCL who are about to undergo autologous stem-cell transplant. Further, I am involved in the Latin America clinical project with our resident-scientist, Dr. Maria Fernandez, that utilizes independent machine learning models to overcome missing variables in clinical data of patients with relapse/refractory TCL to forecast outcomes. As an eager pre-med and aspiring physician, I am motivated to contribute to these projects as they stand to benefit the global understanding of the disease and provide novel therapies to better patient care.

Project: Investigating Super Enhancer Activities in T-Cell Lymphoma

As a physician-scientist, I am dedicated to translational research in hematologic malignancies. My current focus is investigating super-enhancer activities in T-cell lymphoma, aiming to understand the regulatory mechanisms driving disease progression and identify potential therapeutic targets. After completing a residency in hematology, I started research work at RIKEN, studying human hematopoietic and immune development using a humanized mouse system. Subsequently I completed my PhD at Kyoto University on predicting the prognosis of patients who received hematopoietic stem cell transplantation using machine learning algorithms. Outside of the lab, I cherish spending quality time with my family. I also enjoy working out and watching sports, including soccer and rugby.

I am a Postdoctoral Associate at Massachusetts Institute of Technology (MIT) Laboratory for Information and Decision Systems, co-advised by Dr. Devavrat Shah at MIT and Dr. Salvia Jain at Massachusetts General Hospital. My research integrates statistical machine learning, computational genomics, and translational lymphoma research.

Project: Impact of therapy sequence on survival outcomes among patients with relapsed or refractory mature T and NK cell neoplasms: a global retrospective cohort study.

I am a board-certified hematology/oncology clinical pharmacist focused in hematologic malignancies, specifically lymphomas and lymphoproliferative disorders. I received my PharmD at MCPHS University in Boston, MA, completed my clinical training at Rhode Island Hospital/Brown University, and currently completing a Master of Public Health degree with a focus in Biostatistics/Epidemiology at University of Massachusetts. My clinical duties include covering both inpatient lymphoma/ myeloma and medical oncology services and seeing patients with various lymphomas outpatient in the Cancer Center clinic at Massachusetts General Hospital. My clinical areas of interest include immunotherapies, such as T-cell redirecting therapies, therapeutic epigenetics, treatment sequence optimization, and developing high validity observational studies using modern causal inference methods within the target trial framework. A current ongoing area of research is focused on examining how different treatment sequence strategies across multiple lines of therapy may affect the survival of patients with aggressive T and NK cell malignancies. This novel study involves multiple modern methodologies, including machine learning models, to assess and predict survival using one of the largest global cohort of patients with T and NK cell malignancies. This project serves two potentially important functions. Firstly, information here may help inform which therapeutic agents should be used before others in a rare disease with a difficult treatment landscape while considering each person’s unique disease characteristics. Secondly, this may serve as a design framework for future studies in other disease states to optimize personalized decision-making.

I am a Clinical Research Coordinator in the Jain Lab, where I focus on the Super Enhancer Project, studying their role in peripheral T-cell lymphoma (PTCL) tumorigenesis. My work involves identifying super enhancers and their target genes in PTCL cell lines, PDX models, and primary samples, with future efforts aimed at characterizing their mutational landscape and therapeutic relevance. Clinically, I assist in enrolling PTCL patients into the global PETAL consortium. I graduated from Cornell University in 2025, and I am conducting research during my two gap years before medical school. Outside the lab, I enjoy weightlifting, running, snowboarding, and cooking.

I am a Clinical Research Coordinator in the Jain Lab. I am primarily involved in contributing to the Central Pathology Review (CPR) portion of the PETAL Consortium. The overarching goal of CPR is to develop higher quality control of the lymphoma diagnosis process. Increasing the consistency of molecular analysis of cancerous cells will, in the future, allow for more accuracy and personalization in treatment courses and predicted prognoses. I recently graduated from Northeastern University, where I majored in bioengineering with a concentration in computational bioengineering. I am so excited to have the opportunity to work in the Jain Lab and gain more exposure to both clinical and laboratory work on my path to becoming a physician-scientist. Outside of work, I enjoy playing the piano, traveling, and spending time with my friends.

I am a Clinical Research Coordinator in the Jain Lab, where my primary role is supporting the Central Pathology Review (CPR) process for the PETAL Consortium. CPR aims to improve the quality and consistency of lymphoma diagnoses, which will ultimately lead to more accurate molecular characterization of cancerous cells and more personalized approaches to treatment and prognosis. Clinically, I assist with patient enrollment into PETAL clinical trials. I recently graduated from Wellesley College with a degree in biochemistry and am excited to contribute to clinical and translational research during my two gap years before medical school. Outside of work, I enjoy singing, traveling, and going to concerts.

I’m a Research Intern with PETAL Consortium where I contribute to research focused on improving outcomes for patients with peripheral T-cell lymphoma. My work involves supporting clinical research and analyzing patient-level data to better understand treatment patterns, clinical outcomes, and survival across different therapeutic strategies. I’m particularly interested in using epidemiologic and statistical methods to identify factors associated with patient outcomes and to generate evidence that can inform clinical care. Currently, I’m pursuing a Master of Public in Epidemiology at Harvard T.H. Chan School of Public Health and previously earned a Master of Health Science from Johns Hopkins. Outside of research, I enjoy working out, playing guitar, traveling, and exploring Boston.

I am a pre-med student at Cornell University with a strong interest in clinical and translational cancer research.

As a Research Intern with the Jain Lab and PETAL Consortium, I support multicenter lymphoma research through data extraction, organization, and analysis to help generate high-quality datasets for ongoing studies. I also contribute to data monitoring by reviewing clinical data for accuracy and consistency. In addition, I assist with drafting policies for various Consortium committees, supporting the development of standardized research practices and effective collaboration across institutions.

I am grateful for the opportunity to contribute to the PETAL Consortium's impactful research and support collaborative efforts to improve the lives of patients with peripheral T-cell lymphoma.

I'm a clinical research coordinator at the Jain Lab, working as the head of sequencing for the labs projects. I prepare, send, and organize samples to be sequenced, resulting in important data used in bioinformatic analysis. Outside of the lab, I love playing tennis and basketball, watching movies, and cooking.

I'm a pre-med senior at Wellesley College and a research intern for PETAL Consortium. I'm also a content specialist for HOPE-PTCL, PETAL Consortium's patient education website. I am passionate about supporting patients and families facing peripheral T-cell lymphoma through research, education, and clinical care. I hope to expand awareness of resources so patients can access groundbreaking treatments around the globe.

My name is Emmanuel Nwodo, and I’m a pre-med student and incoming senior at Bowdoin College, from Boston, Massachusetts. I am an intern working on communications for the PETAL consortium, preparing content for social media and for the website to spread awareness about the research and T-cell lymphoma. This includes highlighting papers published in various scientific journals, sharing information about team members, and eventually interviewing patients to share their stories of resilience and strength.

I am a pre-med student at the University of Chicago majoring in neuroscience. As a communications intern at PETAL, my work focuses on developing web and social media content that makes information about T-cell lymphoma more accessible to patients, experts, and caregivers while showcasing PETAL’s role in advancing research and collaboration.